Bharat Parenterals Ltd

Bharat Parenter. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Bharat Parenterals Ltd

₹ 1,477 -0.90%
21 Nov 12:21 p.m.
bplindia.in BSE: 541096
About

Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations[1]

Key Points

Business Overview:[1]
BPL is a Gujarat-based WHO GMP & an ISO 10002: 2014, 9001: 2015 certified pharmaceutical company. It manufactures over 800 products spread over 20+ different categories including General Products, β-Lactum/ Cephalosporin Products, Formulations in the form of Tablets, Capsules, Liquid- orals, Ointments, Creams, Lotions, and most importantly Powdered Injections and small Volume Parenterals both in Ampoules and Vials.

Website BSE
  • Market Cap ₹ 964 Cr.
  • Current Price ₹ 1,477
  • High / Low ₹ 1,854 / 554
  • Stock P/E
  • Book Value ₹ 434
  • Dividend Yield 0.07 %
  • ROCE 6.89 %
  • ROE 5.56 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 3.44 times its book value
  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -6.07%
  • The company has delivered a poor sales growth of 3.23% over past five years.
  • Company has a low return on equity of 9.12% over last 3 years.
  • Company might be capitalizing the interest cost
  • Earnings include an other income of Rs.10.6 Cr.
  • Dividend payout has been low at 2.21% of profits over last 3 years
  • Company has high debtors of 201 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
60 38 52 26 82 59 51 70 60 60 68 93 72
50 36 48 24 73 56 45 59 55 53 67 88 79
Operating Profit 10 3 4 2 9 3 6 10 4 7 1 4 -8
OPM % 17% 7% 8% 7% 11% 4% 12% 15% 7% 11% 1% 5% -11%
3 1 2 2 6 3 0 2 3 1 3 3 4
Interest 0 0 0 0 0 1 1 1 1 1 1 3 3
Depreciation 2 2 2 2 1 1 1 2 2 2 4 9 9
Profit before tax 11 2 5 2 14 4 4 10 5 5 -1 -5 -15
Tax % 26% 42% 16% 28% 29% 36% 47% 30% 46% 33% 88% 85% 14%
8 1 4 1 10 2 2 7 2 4 -3 -9 -18
EPS in Rs 13.88 2.34 7.00 2.03 17.18 4.94 4.31 13.02 6.05 6.50 -0.52 1.96 -11.51
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
124 111 137 220 228 205 212 218 257 292
114 105 124 191 200 179 183 198 234 287
Operating Profit 10 7 12 29 28 25 29 20 23 4
OPM % 8% 6% 9% 13% 12% 12% 14% 9% 9% 2%
5 8 7 13 11 9 7 12 9 11
Interest 1 1 1 1 1 1 1 3 4 7
Depreciation 4 6 6 6 6 6 7 6 9 24
Profit before tax 9 7 13 35 33 27 28 24 19 -16
Tax % 31% 8% 29% 39% 26% 25% 25% 33% 44%
6 7 9 21 24 20 21 16 11 -25
EPS in Rs 11.26 12.03 15.92 37.09 42.13 35.59 36.45 28.47 24.95 -3.57
Dividend Payout % -0% -0% -0% -0% -0% -0% -0% 3% 4%
Compounded Sales Growth
10 Years: %
5 Years: 3%
3 Years: 8%
TTM: 22%
Compounded Profit Growth
10 Years: %
5 Years: -13%
3 Years: -19%
TTM: -192%
Stock Price CAGR
10 Years: %
5 Years: 52%
3 Years: 61%
1 Year: 162%
Return on Equity
10 Years: %
5 Years: 12%
3 Years: 9%
Last Year: 6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 6 6 6 6 6 6 6 6 6 7
Reserves 51 58 67 88 112 138 160 177 191 277
19 6 9 5 1 12 18 50 158 130
44 40 50 60 68 43 42 118 149 129
Total Liabilities 120 110 132 159 188 199 226 350 504 542
35 31 34 35 33 45 41 42 210 205
CWIP -0 -0 -0 1 12 0 26 99 25 25
Investments 0 1 1 1 0 43 11 -0 -0 -0
85 79 98 121 142 111 148 209 269 312
Total Assets 120 110 132 159 188 199 226 350 504 542

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-0 -2 6 20 14 24 -1 22 -5
-0 -2 -8 -9 -13 -43 -7 -78 -105
-0 -8 4 -4 -3 10 9 61 110
Net Cash Flow -0 -11 2 7 -1 -8 2 4 1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 130 143 157 106 127 121 126 188 201
Inventory Days 62 70 60 59 71 61 56 100 142
Days Payable 171 168 110 83 104 71 64 136 138
Cash Conversion Cycle 21 45 107 82 93 111 118 152 204
Working Capital Days 45 64 92 76 89 112 157 156 201
ROCE % 11% 18% 39% 31% 20% 17% 11% 7%

Shareholding Pattern

Numbers in percentages

Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Oct 2024
73.84% 73.84% 73.84% 73.84% 73.84% 73.84% 73.84% 73.84% 73.27% 73.27% 65.35% 67.20%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.08% 0.08%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.57% 0.54%
26.15% 26.15% 26.16% 26.16% 26.15% 26.16% 26.15% 26.15% 26.72% 26.72% 33.98% 32.17%
No. of Shareholders 2,7962,7652,7002,6082,5152,4852,4812,3972,4972,7082,7482,750

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls

  • May 2024
    Transcript
    Notes
    PPT
  • Feb 2024
    Transcript
    Notes
    PPT